Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough…
HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for…
ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing…
1-For-20 Ratio Change Initiated to Increase Per Share Market Price of Amarin’s ADSs in Effort to Maintain Nasdaq ListingDUBLIN and…
COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic…
-- Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024…
Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activitiesGAITHERSBURG, Md., March 12, 2025…
Strategic investment in digital health solutions addressing critical challenges in primary care and chronic disease management Rome, Italy, 12 March…
PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment…
Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize…